Abstracts

317 – Effectiveness of Messenger RNA–Based Vaccines Among People With HIV: A Case-Control Study

Background In people living with HIV (PLWH), persistent immune activation remains despite virologic suppression with antiretroviral therapy, thereby reducing vaccine effectiveness. Current guidelines recommend strengthened and individualized vaccination strategies, with viral suppression and immune reconstitution as essential prerequisites. The aim of the study is to evaluate whether chronic HIV infection may also impact the effectiveness of the…

324 – Comparison of Subcutaneous Versus Intradermal Administration of MVA Vaccine Booster Dose

Background MVA-BN vaccination is now considered the primary preventive measure against mpox infection. A booster dose administered at least two years after the primary vaccination significantly enhances both humoral and cellular immunity. Assessing whether the subcutaneous (SC) or intradermal (ID) administration route influences the magnitude of the response may inform public health strategies for maximizing…

363 – IL-1β Blockade Reprograms Antiviral Immunity and CD8+ T-Cell Responses to Reduce the HIV Reservoir

Background Chronic inflammation contributes to immune dysregulation in people with HIV (PWH), even during suppressive antiretroviral therapy (ART). While IL-1b is a key inflammatory mediator, its blockade has not been mechanistically studied in this context. We investigated the immunologic effects of IL-1b inhibition using Canakinumab (Cana), a monoclonal antibody targeting IL-1b, in ART-suppressed PWH. Methods…

304 – mRNA-Encoded bNAb PGT121-LS: Preclinical Characterization and Pharmacokinetics in Nonhuman Primates

Background Recombinant broadly neutralizing antibodies (bNAbs) are a promising therapeutic approach against HIV but may face manufacturing challenges. mRNA-encoded bNAbs (RibobNAbs) provide an alternative mode of delivery, characterized by rapid production and in vivo assembly, circumventing the challenges of recombinant antibody production. As proof of concept, we developed bNAb PGT121, featuring half-life extending LS mutations,…

818 – Pre-ART Vertical HIV Transmission Rates in Uganda Vary by Sex of Child and Maternal Viral Subtype

Background In adults, HIV-1 subtype A is associated with higher rates of heterosexual transmission, whereas subtype D is linked to faster disease progression. Less is known about the impact of subtype in perinatal transmission, although data indicate a greater susceptibility of female infants to perinatal acquisition. Here, we evaluated the impact of infant sex and…

837 – Impact of Early Treatment Initiation After Perinatal HIV Infection on Intact Provirus Levels

Background Early ART initiation in children with perinatal HIV-1 infection reduces significantly the overall reservoir size. However, few studies assessed its impact on reservoir composition, particularly genetically intact, potentially replication-competent proviruses. From the ANRS-MIE-EP59 CLEAC study, we investigated whether early ART initiation affects reservoir intactness during childhood and adolescence. Methods The study included children (5-12 yrs) and…

1036 – Doxycycline Postexposure Prophylaxis Impact on Neisseria gonorrhoeae Antimicrobial Susceptibility

Background Antimicrobial resistance in gonorrhea is a growing concern. Doxycycline post-exposure prophylaxis (DoxyPEP) has been proposed to reduce bacterial sexually transmitted infections (STIs). Aim is to assess DoxyPEP impact on gonorrhea antimicrobial susceptibility. Methods This is a retrospective study including people with culture-positive gonorrhea infections diagnosed between 2022-2025 at San Raffaele Institute, Milan, Italy. Minimum inhibitory…

1040 – Real-World Clinical Outcomes of Doxycycline Postexposure Prophylaxis for Bacterial STI Prevention

Background Doxycycline post-exposure prophylaxis (DoxyPEP) prevents bacterial STIs in trials, but real-world effectiveness and safety signals remain uncertain. Methods We reviewed people presenting to a community sexual health clinic in Providence, Rhode Island from May 2023 to July 2025. We summarized demographics and DoxyPEP awareness and uptake, as well as modeled encounter-level associations between time-varying…